Nothing said here yet.
to join the conversation.
| Leoni MollieChief Medical Officer | Sell | 28,802 | $309.6K | Tue, Sep 29 |
| Powl Brian T.Chief Commercial Officer | Sell | 15,430 | $165.9K | Tue, Sep 29 |
| FORD KATHLEENChief Operating Officer | Sell | 3,668 | $39.4K | Tue, Sep 29 |
| Leoni MollieChief Medical Officer | Sell | 12,448 | $130.7K | Mon, Sep 28 |
| Powl Brian T.Chief Commercial Officer | Sell | 9,020 | $94.7K | Mon, Sep 28 |
| Bair Teresa BrophyChief Legal Officer | Sell | 8,442 | $88.6K | Mon, Sep 28 |
| Powl Brian T.Chief Commercial Officer | Sell | 8,000 | $84.5K | Mon, Sep 28 |
| FORD KATHLEENChief Operating Officer | Sell | 6,906 | $72.5K | Mon, Sep 28 |
| DOYLE THOMAS JAMESSVP, Finance & Accounting | Sell | 4,607 | $48.4K | Mon, Sep 28 |
| Burrows FrancisChief Scientific Officer | Sell | 20,726 | $224.5K | Thu, Sep 24 |
| WILSON TROY EDWARDPresident and CEO | Buy | 100,000 | $1.2M | Mon, Aug 24 |
| Powl Brian T.Chief Commercial Officer | Sell | 4,345 | $51.7K | Fri, Aug 21 |
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and…
Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy.
Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain.
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.